• Login
    • Join
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Exclusives
    • Manufacturing
    • Markets
    • Top 10 Orthopedic Device Firms
    • Buyers' Guide
    • Events
    • More
  • Magazine
  • News
  • Exclusives
  • Manufacturing
  • Markets
  • Top 10 Orthopedic Device Firms
  • Buyers' Guide
  • Events
  • Current & Past Issues
    Features
    Departments
    Columns
    Editorial
    Digital Edition
    Subscribe Now
    Advertise Now
    Editorial Guidelines
    eNewsletter Archive
    Top Features
    The 11 Steps of Metrology Matching

    Realizing the Promise of Pre-Validated Packaging

    Creating a Natural Extension: Instrument Manufacturing

    Squeaky Clean: Orthopedic Device Packaging & Sterilization

    Natural Selection: Biologics in Orthopedics
    Breaking News
    Certifications
    Clinical Trials
    Device Approvals & Patents
    Financial & Deals
    International
    Market Data & Trends
    OEM News
    People
    Product & Service Releases
    Products
    Quality, Recalls & Risk
    Regulatory & Legal
    Supplier & Contract Mfg.
    Live From Shows
    Top News & Features
    Nevro Files U.S. Patent Lawsuit Against Stimwave

    Global Study Finds High Success Rate for Hip and Knee Replacements

    Life Spine Announces Initiation of SIMPACT Sacroiliac Joint Fixation Outcomes Study

    McGinley Orthopedics Recruits Industry Leader as New CEO

    Study Shows Safety, Efficacy of Radiological Outcomes for Oblique Lateral Lumbar Interbody Fusion
    3-D Printing/Additive Mfg.
    Assembly & Automation
    Biocompatibility & Testing
    Clean Room
    Coatings/Surface Modification
    Contract Manufacturing
    Design
    Extrusion
    Finishing
    Forging & Casting
    Instruments, Cases & Trays
    International/Offshoring
    Laser Processing
    Materials
    Machining & Tooling
    Molding
    Packaging & Sterilization
    Prototyping
    Research & Developement
    Software & Quality
    Staffing, Training & Prof. Dev.
    Supply Chain

    Nevro Files U.S. Patent Lawsuit Against Stimwave

    Global Study Finds High Success Rate for Hip and Knee Replacements

    McGinley Orthopedics Recruits Industry Leader as New CEO

    Study Shows Safety, Efficacy of Radiological Outcomes for Oblique Lateral Lumbar Interbody Fusion

    Strengthening Muscular Rehabilitation with Objective Clinical Data
    Biologics
    Bracing/Prosthetics
    Extremities
    Imaging
    Instruments
    Large Joint
    MIS/Robotics
    Spine/Neurology
    Trauma/Sports
    Top Markets
    Strengthening Muscular Rehabilitation with Objective Clinical Data

    Nail Simplifies Two-Procedure Rotator Cuff Repair

    Treating that Pain-in-the-Neck Smartphone

    Sounding Board: 2018 Reflections and Looking Ahead

    Creating Customized Orthopedic Products Using Handheld 3D Scanners
    Companies
    Categories
    Company Capabilities
    White Papers
    Add New Company
    International Buyers Guide Companies
    Teleflex Medical OEM

    Medbio Inc.

    Gauthier Biomedical Inc.

    Five Star Manufacturing Inc.

    Huron Tool & Cutter Grinding Co. Inc.
    Industry Events
    Webinars
    • Magazine
      • Current & Past Issues
      • Features
      • Editorial
      • Departments
      • Columns
      • Digital Edition
      • eNewsletter Archive
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
    • Breaking News
    • Buyers' Guide
      • Companies
      • Categories
      • Company Capabilities
      • White Papers
      • Add Your Company
    • Manufacturing
      • 3-D Printing/Additive Mfg.
      • Assembly & Automation
      • Biocompatibility & Testing
      • Clean Room
      • Coatings/Surface Modification
      • Contract Manufacturing
      • Design
      • Extrusion
      • Finishing
      • Forging & Casting
      • Instruments, Cases & Trays
      • International/Offshoring
      • Laser Processing
      • Materials
      • Machining & Tooling
      • Molding
      • Packaging & Sterilization
      • Prototyping
      • Research & Developement
      • Software & Quality
      • Staffing, Training & Prof. Dev.
      • Supply Chain
    • Markets
      • Biologics
      • Bracing/Prosthetics
      • Extremities
      • Imaging
      • Instruments
      • Large Joint
      • MIS/Robotics
      • Spine/Neurology
      • Trauma/Sports
    • Top 10 Orthopedic Device Firms
    • Online Exclusives
    • Slideshows
    • Videos
    • Webinars
    • Events
      • Industry Events
    • Live from Show Event
    • About Us
      • About Us
      • Contact Us
      • Privacy Policy
      • Terms of Use
      • Advertise With Us
    Columns

    Data Monitoring Committees: Making DMCs Work for Your Study

    Related CONTENT
    • FDA Initiates Device Development Challenge to Help Combat Opioid Crisis
    • Autocam Medical
    • Empirical Machine Earns FDA Contract Manufacturer Designation
    • FDA Defines 'Radiological Computer Assisted Detection and Diagnosis Software'
    • Lipogems Receives FDA Clearance For Microfragmented Adipose Tissue System
    Margeaux Rogers, Senior Associate, Regulatory Affairs, Musculoskeletal Clinical Regulatory Advisers LLC11.30.18
    The use of independent data monitoring committees is becoming increasingly prevalent in the U.S. medtech industry. The FDA outlines these groups and their operation in a 12-year-old guidance due to expire at the end of this year. However, the composition of these groups, their respective responsibilities, and how best to make them work for a particular study design is often unclear.

    Purpose of Data Monitoring Committees
    While sponsors are required to monitor studies, the FDA has increasingly requested independent reviews of study data by data monitoring committees (DMCs). In MCRA’s recent experience with device trials, FDA has requested the use of one or more DMC groups for all premarket approval and 510(k) submissions with clinical data, even in cases where independent oversight was not required in the original IDE.

    In device studies, DMCs take the form of a medical monitor, clinical events committee (CEC), and data safety monitoring board (DSMB). Whether used separately or in parallel, these groups are necessary to ensure validity and scientific merit of the trial by providing additional, independent assessments of safety events. DMCs also ensure reliable data pooling across multi-center trials and comparisons with historical controls or published data.

    DMCs generally are comprised of independent experts who are convened to oversee and ensure the most rigorous study conduct and data validity, though each group serves a different role. Depending on the study design and the device’s risk-benefit profile, the study may not require oversight from all three groups. For instance, a total disc replacement study with a straightforward statistical plan typically only requires a CEC. It is important to understand the different types of DMCs to develop an appropriate plan for the study design. The traditional functions of these groups and least burdensome considerations for DMC assembly are described below.

    Medical Monitor
    Medical monitors oversee the clinical study’s conduct, including the safety of all enrolled study subjects. An ideal Medical Monitor is a well-respected key opinion leader in the medical community with experience in the target therapeutic area. The medical monitor serves as a resource to the trial sponsor, clinical research organization (if applicable), and investigational sites to discuss and provide input on study-related topics. The monitor also may serve as a resource to the DSMB or CEC by answering questions about patient eligibility, concomitant treatments/medications, and any potential safety events.

    Device studies typically employ a single medical monitor who’s involved for the duration of the study on an as-needed basis. The medical monitor’s responsibilities may include reviewing protocol waiver requests, discussions with sponsors and sites regarding retraining of sites, or surgeon-to-surgeon discussion of technique. Medical monitors also help the trial sponsor implement DSMB recommendations like site conduct changes. Most importantly, medical monitors may serve as independent reviewers of serious adverse events to determine if they should be reported to the IRB or FDA.

    Above all, medical monitors act as an independent, qualified intermediary between site investigators and the CRO or sponsor. The medical monitor lets the sponsor be one step removed from the decision-making process involving enrollment decisions and AE definitions, and allows for physician-to-physician discussion when retraining is necessary (for the study or surgical techniques).

    Clinical Events Committee
    The CEC is an independent committee of medical experts that reviews specific information obtained from clinical trial subjects. Its primary role is to review and adjudicate individual clinical events based on protocol-specific definitions that may be subject to interpretation by the sites. CEC review ensures that events critical to the analysis of study results are assessed in a uniform manner, eliminating the variability associated with site-based event evaluation. This facilitates reliable data pooling within a trial and improves the validity of comparisons with published data.

    CECs review event level data with the intent of confirming or adjudicating the investigators’ classification. In some cases, the CEC may assign classifications the investigator did not make. For instance, in cases where adverse event severity was not captured in the study, the CEC may assign severity. Common endpoints reviewed include adverse events, secondary surgical interventions, and protocol deviations. In addition to study endpoints, the CEC can provide an assessment of other events or areas of concern at the request of the DSMB or sponsor.

    Data Safety Monitoring Board
    DSMBs are responsible for ensuring study participants’ safety and monitoring the overall conduct of the clinical trial. The DSMB evaluates the risks and benefits to subjects based on accrued and available data, and advises the sponsor of any safety concerns and other issues important to the study’s safe conduct. In particular, the DSMB advises about the continuing safety of current participants and those yet to be recruited, as well as the trial’s continuing validity and scientific merit.

    A DSMB is an independent, multidisciplinary group composed of at least one clinician with experience specific to the therapeutic area, at least one statistician experienced in device trial statistics, and an additional member with relevant expertise. DSMBs identify study-wide issues through review of aggregate study data and detailed safety information. Following review, the group provides a recommendation to study sponsors to terminate the study, continue with modification, or continue without modification.

    This group is commonly used in early feasibility studies, adaptive trial designs, or for devices with unique safety risks. In early feasibility or first-in-man studies, DSMBs may review data to determine feasibility or futility of the treatment/study. In adaptive study designs, DSMBs may review data to make enrollment recommendations or to make an early claim to end enrollment. DSMBs may also be tasked with reviewing particular device-related adverse events to ensure they do not exceed a predefined rate, as defined in the study “stopping rules.” The frequency and scope of DSMB review should be tailored to the specific study design.

    Member Selection
    While varied in composition and scope, each oversight committee serves an advisory role. As such, members should be seasoned experts in the therapeutic area or their respective area, free of conflicts of interest that would jeopardize their independence or judgment, and should be committed to serving in their respective role for the duration of the trial. MCRA recommends keeping location and time zone in mind when recruiting group members. It is best to find a medical monitor who is in the same time zone as the trial sponsor or the majority of study sites to facilitate timely study communication between the respective parties. MCRA has found in-person CEC meetings and WebEx DSMB meetings to be most successful. To facilitate in-person meetings, we typically recruit members in the same metro area. While this is not necessary for WebEx meetings, it is important to keep time zones in mind as this affects scheduling availability.

    Integrated Approach to Preparing for DMC Review
    When preparing for a DMC data review, it is important to assemble a strong support team that includes key members of the data management team, biostatistics group, monitors, and project managers. Data planned for CEC review should be fully monitored and free of all queries. Adverse events should be resolved at the time of review (resolved, or ongoing with no further expected improvement) or the patient should have exited the study. Preparing for safety oversight meetings requires source documentation from sites and complete narratives of all safety events subject to review. Data management is needed to identify eligible events, export data, and input/house adjudication data. Study statisticians play a large role in data presentation to DSMB groups as well as table development for CEC review. Data planned for DSMB review should have been previously reviewed by the CEC, if applicable. Enrollment thresholds or adverse event rates may drive DSMB review timing. Strong project management is necessary to coordinate the various groups and activities.

    Least Burdensome Considerations
    Employing all three DMCs can be incredibly burdensome to study sponsors in terms of both clinician consulting costs and internal human resources. Steps can be taken while organizing committees to reduce this burden. The medical monitor role can also be performed by the sponsor’s internal medical director or study’s lead investigator. As stated previously, studies of devices with well-defined risk-benefit profiles and straightforward statistical plans may not need DSMB review. Studies required to have DSMBs can pre-specify annual review frequency unless triggered by certain events. Similarly, the CEC process can be scaled down unless otherwise directed by FDA. Sponsors can propose a limited review of adverse events with certain classes, severities, or relationships. CECs may also set precedents to facilitate review and adjudication of common events.

    While it is easier to outline and execute a DMC plan early in the IDE process, these programs can be implemented after study start-up or retrospectively. MCRA can help sponsors develop the least burdensome DMC oversight program for their studies by determining which safety oversight groups are needed, selecting members of safety oversight groups, and providing full project management. 

    Organizational overview of Data Monitoring Committees
      Medical Monitor CEC DSMB
    Recommended Composition 1 member: clinician or key opinion leader in therapeutic area 3 members: clinicians (with option for one radiologist) specializing in therapeutic area 3 members: at least one clinician with experience in the therapeutic area and one biostatistician experienced in clinical trial design
    Primary Responsibility Resource for CRO, sites and sponsor with recommendation to modify site or study level conduct. Resource for DSMB/CEC as requested. Review of individual safety events with recommendation to adjudicate event classification Review of aggregate analyses with recommendation to terminate study, continue with modification, or continue without modification
    Communication Plan Receives questions from and provides recommendations to sponsor/CRO, study investigators, DSMB or CEC Receives review materials for individual events from DMC project manager and provides adjudication data to DMC project manager for entry into database and communication to study sites Receives analyses from statistical group, provides recommendations to sponsor
    Timing of Interaction Communication as requested Quarterly, or as needed based on number of accrued events Annually, semi-annually, or upon completion of each interim safety analysis
    Common Tasks Enrollment waivers; memos to study investigators to clarify protocol or other aspects of study conduct Review of AEs, SSIs, neurologic deterioration, protocol deviations, patient eligibility at the event level Review of aggregate data and safety events for overall safety or stopping rule requirements; review of data for enrollment termination if applicable for study design



    Margeaux Rogers is a senior regulatory associate at MCRA, primarily focusing on developing regulatory strategies and submissions for FDA, as well as international regulatory agencies. She has extensive knowledge of regulatory pathways with experience developing PMAs, IDEs, 510(k)s, and clinical evaluation reports, with a focus in orthopedic devices. Rogers also frequently manages CECs and DSMBs for study sponsors. 
    Related Searches
    • research
    • FDA
    • surgeon
    • patient
    Suggested For You
    Material Matters: New Offerings for Orthopedic Technologies Material Matters: New Offerings for Orthopedic Technologies
    FDA Plans to Modernize 510(k) Program FDA Plans to Modernize 510(k) Program
    Simplify Medical Completes Enrollment in U.S. IDE Pivotal Trial of Simplify Disc Simplify Medical Completes Enrollment in U.S. IDE Pivotal Trial of Simplify Disc
    RTI Surgical to Acquire Paradigm Spine RTI Surgical to Acquire Paradigm Spine
    NASS News: Spineology Presents 12-Month Data for SCOUT Trial NASS News: Spineology Presents 12-Month Data for SCOUT Trial
    Zimmer Biomet Spine Announces FDA Approval of Mobi-C Cervical Disc Labeling Extension Zimmer Biomet Spine Announces FDA Approval of Mobi-C Cervical Disc Labeling Extension
    RTI Surgical Features Next-Gene Spine Implant Technologies at NASS RTI Surgical Features Next-Gene Spine Implant Technologies at NASS
    Giving Back: An Examination of the Spine Technologies Sector Giving Back: An Examination of the Spine Technologies Sector
    Do New Structures Redefine Do New Structures Redefine 'Material'?
    Amedica Announces Completion of First Valeo C+CSC With Lumen Interbody Fusion Surgery Amedica Announces Completion of First Valeo C+CSC With Lumen Interbody Fusion Surgery
    Bright Horizons: Highlighting Six Orthopedic Technology Companies to Watch Bright Horizons: Highlighting Six Orthopedic Technology Companies to Watch
    Effects of MEDDEV Revision 4 on Clinical Evaluation Reports (Part 2) Effects of MEDDEV Revision 4 on Clinical Evaluation Reports (Part 2)
    FDA’s Educational Opportunities Abound FDA’s Educational Opportunities Abound
    RTI Surgical & Aziyo Biologics Partnership Expands Access to ViBone Bone Repair RTI Surgical & Aziyo Biologics Partnership Expands Access to ViBone Bone Repair
    NuVasive Unveils Spine NuVasive Unveils Spine's First Integrated Surgical Automation Platform

    Related Columns

    • An Industry on the Defensive

      An Industry on the Defensive

      It’s been a rough six months for the medtech industry. Nearly 200 days after it was first blindsided by a one-two punch of bad publicity from the damning Netflix documentary “The Bleeding Edge,” the sector remains firmly immersed…
      Michael Barbella, Managing Editor 02.13.19

    • Medtech and The Management Top 250

      Medtech and The Management Top 250

      Developed by the Drucker Institute and publicized by The Wall Street Journal, The Management Top 250 Ranking measures and ranks corporate competencies from 1-250 by scrutinizing operations in five areas: customer satisfaction, employee engagement and…
      Maria Shepherd, President and Founder, Medi-Vantage 02.13.19

    • 3-D Printing/Additive Mfg.
      The Gawky Teenage Phase: 3D Printing Enters Adolescence

      The Gawky Teenage Phase: 3D Printing Enters Adolescence

      As the mom of a young teen, I get a daily, real-time view of the of the challenges of a human doing his best to grow up. There are a lot of false starts, half-baked ideas, and epic fails, but there’s also tremendous potential and frequent victo…
      Dawn A. Lissy, President & Founder, Empirical 02.13.19


    • 3-D Printing/Additive Mfg. | Biologics | MIS/Robotics
      Getting a Clinical Viewpoint

      Getting a Clinical Viewpoint

      Last year, at the North American Spine Society’s (NASS) 33rd Annual Meeting, held in Los Angeles, Jeffrey C. Wang, M.D., professor of orthopaedic surgery and neurological surgery (clinical scholar) at the Keck Medical Center at the University o…
      Sean Fenske, Editor-in-Chief 02.13.19

    • Design | Research & Development
      Trial Master File: Paper or Electronic?

      Trial Master File: Paper or Electronic?

      The Trial Master File (TMF) is the central location for all clinical trial documents. From the start of a clinical trial through its conclusion, the TMF contains and secures a variety of information such as signature pages, study logs, ethics committ…
      Anuradha Nagulapati, Clinical Research Associate, Musculoskeletal Clinical Regulatory Advisers 02.13.19

    • Software & Quality
      2019: The Year to Enhance Quality in Orthopedic Product Development

      2019: The Year to Enhance Quality in Orthopedic Product Development

      The world has gone digital, and now it’s time for orthopedic product developers and manufacturers to catch up. According to LNS Research, 60 percent of all organizations are investing in industrial transformation—otherwise known as digita…
      Anthony Parise, Product Strategist—Life Sciences, ETQ 02.13.19


    • Biologics | MIS/Robotics | Trauma/Sports
      Global Prospects in Orthopedics

      Global Prospects in Orthopedics

      Camil Moldoveanu was fully prepared for the challenge. Or so he thought. The four-time Brazilian jiu-jitsu world champion knew he would need significant rehabilitation for his knee injury. He also knew the recovery process would be difficult, and…
      Michael Barbella, Managing Editor 11.30.18

    • Spine/Neurology
      Leveraging Innovation to Address the Opioid Crisis

      Leveraging Innovation to Address the Opioid Crisis

      The news has been devastating; according to the National Institute on Drug Abuse (NIDA) website, “every day, more than 115 people in the United States die after overdosing on opioids…including prescription pain relievers, heroin, and syn…
      Maria Shepherd, President and Founder, Medi-Vantage 11.30.18

    • Design | Research & Development
      MPO Summit: The View from the Top

      MPO Summit: The View from the Top

      It started with a wintry dusting of snow and ended in a blaze of autumnal glory. On top of a mini tour of Colorado’s best seasons, the two-day MPO Summit in Broomfield on Oct. 11-12 offered forecasts and insights into what it takes to weather c…
      Dawn A. Lissy, President & Founder, Empirical 11.30.18


    • MDSAP Audits Update: Progress, Challenges, and a Cost Reduction Case Study

      MDSAP Audits Update: Progress, Challenges, and a Cost Reduction Case Study

      The Medical Device Single Audit Program (MDSAP) is growing fast, with 3,629 sites now participating, as compared to just 788 at the end of 2017. Part of this explosive growth stems from the fact that Canada will require manufacturers to comply wit…
      Anthony Parise, Product Strategist—Life Sciences, ETQ 11.30.18

    • Top 10 Findings from a Warning Letter Analysis

      Top 10 Findings from a Warning Letter Analysis

      When I first started out in medtech, I did not have a good appreciation for quality systems. I was working as an engineer at the time, and I found quality systems quite a nuisance because any change I proposed was either restricted or not allowed due…
      Linda Braddon, Ph.D., President and CEO, Secure BioMed Evaluations 11.30.18

    • Extremities | Large Joint | Materials | Spine/Neurology
      Recycling Implanted Metals From Beyond the Grave

      Recycling Implanted Metals From Beyond the Grave

      Ever wonder what happens to devices implanted in the body after their users pass away? Probably not, because the thought of it tends to make most people who aren’t ODT editors cringe. But as medical implants become more common, people are dy…
      Sam Brusco, Associate Editor 09.19.18

    • MIS/Robotics
      Premium Medtech Price Stategies for the Orthopedic Robotics Segment

      Premium Medtech Price Stategies for the Orthopedic Robotics Segment

      Growth in the market for surgical robots used in hip and knee orthopedic procedures was forecasted at $222 million in 2015 with anticipated growth to reach $5 billion by 20221 (Table 1). A substantial number of next- generation robotic devices, syste…
      Maria Shepherd, President and Founder, Medi-Vantage 09.19.18

    • A Different Class of Engineer: How to Connect with Rising Medtech Talent

      A Different Class of Engineer: How to Connect with Rising Medtech Talent

      My grandfather—a World War II veteran who worked at GE in my native Cleveland—was one of my most beloved family members. When I told him I wanted to study engineering in college, he told me to find a university where I could get real, on-…
      Dawn A. Lissy, President & Founder, Empirical 09.19.18

    • Getting Started on the Right Foot: Initiating Orthopedic Clinical Trials

      Getting Started on the Right Foot: Initiating Orthopedic Clinical Trials

      Initiating an orthopedic clinical trial (OCT) is an exciting milestone for companies as years of pre-clinical testing and conversations with the U.S. Food and Drug Administration (FDA) finally come to fruition. Focusing on specific elements of the st…
      Bhavana Shivakumar , Clinical Research Associate, Musculoskeletal Clinical Regulatory Advisers LLC 09.19.18


    Breaking News
    • Nevro Files U.S. Patent Lawsuit Against Stimwave
    • Global Study Finds High Success Rate for Hip and Knee Replacements
    • Life Spine Announces Initiation of SIMPACT Sacroiliac Joint Fixation Outcomes Study
    • McGinley Orthopedics Recruits Industry Leader as New CEO
    • Study Shows Safety, Efficacy of Radiological Outcomes for Oblique Lateral Lumbar Interbody Fusion
    View Breaking News >
    CURRENT ISSUE

    January/February 2019

    • The 11 Steps of Metrology Matching
    • Realizing the Promise of Pre-Validated Packaging
    • Creating a Natural Extension: Instrument Manufacturing
    • Squeaky Clean: Orthopedic Device Packaging & Sterilization
    • Natural Selection: Biologics in Orthopedics
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • privacy policy
    • term and condition
    • about us
    • contact us

    follow us

    Subscribe

    magazines

    Image
    Image
    Image
    Image
    Image
    Image
    Image
    Image
    Image
    Image
    Image

    Copyright © 2019 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login